{"product_id":"biolegend-329927","title":"Biolegend, 329927, Brilliant Violet 711™ anti-human CD279 (PD-1) Antibody, 25tests","description":"\u003cp\u003eProgrammed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.\u003cbr\u003e\n25tests\u003cbr\u003e\nVerified Reactivity: Human\u003cbr\u003e\nReported Reactivity: African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Mouse\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™ under optimal conditions.\u003cbr\u003e\nConcentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710\/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.\u003cbr\u003e\nExcitation Laser: Violet Laser (405 nm)\u003cbr\u003e\nApplication Notes: Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF™ purified antibody (Endotoxin \u0026lt;0.1 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin \u0026lt;0.01 EU\/µg).\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA) Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA) Velu V, et al. 2007. J. Virol. 81:5819. (FA) Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA) Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity) Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC) Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG) Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed\u003cbr\u003e\nProduct Citations: Korniotis S, et al. 2022. J Cell Sci. 135:. PubMed Lee K, et al. 2023. JCI Insight. 8:. PubMed Adamo S, et al. 2023. Cell Host Microbe. 31:928. PubMed Keeton R 2023. Cell Reports Medicine. 4(1):100898. PubMed Clark IC, et al. 2023. Nature. 614:318. PubMed Gartshteyn Y, et al. 2023. Life Sci Alliance. 6: . PubMed Cheng H, et al. 2023. Nat Metab. 5:314. PubMed Khojandi N, et al. 2021. Cancer Immunol Res. 9:214. PubMed Judge CJ, et al. 2017. J Leukoc Biol. 102:171. PubMed Yero A, et al. 2019. J Virol. 93:e00371-19. PubMed Guedan S, et al. 2018. JCI Insight. 3. PubMed Keeton R, et al. 2021. Cell Host Microbe. 29:1611. PubMed Ferrando-Martinez S, et al. 2018. J Clin Invest. 128:2089. PubMed Guedan S, et al. 2020. J Clin Invest. 130:3087. PubMed Thompson EA, et al. 2021. Cell Rep. 108863:34. PubMed Bradley T et al. 2018. Cell. 175(2):387-399 . PubMed Studniberg SI, et al. 2022. Mol Syst Biol. 18:e10824. PubMed Bochem J, et al. 2019. PLoS One. 14:e0221301. PubMed Gao Y, et al. 2022. Immunity. 55:1732. PubMed Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed Wing A, et al. 2018. Cancer Immunol Res. 6:605. PubMed Heard A, et al. 2022. Nat Commun. 13:3367. PubMed Wilson TL, et al. 2022. Cancer Discov. 12:2098. PubMed Lecciso M, et al. 2017. Front Immunol. . 10.3389\/fimmu.2017.01918. PubMed Zheng Z, et al. 2017. PLoS One. 10.1371\/journal.pone.0184127. PubMed Giron LB, et al. 2020. EBioMedicine. 73.94791667. PubMed Ma S, et al. 2022. Nat Commun. 13:4118. PubMed Moysi E, et al. 2021. Front Immunol. 12:683396. PubMed\u003cbr\u003e\nRRID: AB_11218612 (BioLegend Cat. No. 329927) AB_2562911 (BioLegend Cat. No. 329928)\u003cbr\u003e\nStructure: Immunoglobulin superfamily\u003cbr\u003e\nDistribution: Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells\u003cbr\u003e\nLigand\/Receptor: B7-H1 (also known as PD-L1) and B7-DC (PD-L2)\u003cbr\u003e\nCell Type: B cells, Lymphocytes, T cells, Thymocytes, Tregs\u003cbr\u003e\nBiology Area: Cancer Biomarkers, Immunology, Inhibitory Molecules\u003cbr\u003e\nMolecular Family: CD Molecules, Immune Checkpoint Receptors\u003cbr\u003e\nGene ID: 5133\u003cbr\u003e\nUniProt: View information about CD279 on UniProt.org\u003cbr\u003e\nClone: EH12.2H7\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: PD-1, PDCD1\u003cbr\u003e\nIsotype: Mouse IgG1, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46863074885801,"sku":"329927","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/biolegend-329927","provider":"Iright","version":"1.0","type":"link"}